The influence of ROS1 fusion partners and resistance mechanisms in ROS1 ‐ TKI ‐treated non‐small cell lung cancer patients
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.70109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Fenneke Zwierenga und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, University of Groningen, University Medical Center Groningen, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proto-Oncogene Proteins, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Clinical outcomes in ROS1 ‐fusion positive ( ROS1 +) non‐small cell lung cancer (NSCLC) by fusion partner and resistance mechanisms are limited. This cohort study included 56 ROS1+ patients (FISH or NGS confirmed); fusion partners were identified in 27 cases, including CD74 ( n = 10), EZR ( n = 7), and SDC4 ( n = 7). Clinical data were available for 50 patients (median age 62; 51% female; 32% never‐smokers). Forty patients received tyrosine kinase inhibitors (TKIs), mostly crizotinib ( n = 38). Crizotinib showed a 55% objective response rate (ORR) and a median progression‐free survival (mPFS) of 5.3 months. Brain metastases (HR 2.65, 95% CI 1.06–6.60, P = 0.037) and prior chemotherapy (HR 3.17, 95% CI 1.35–7.45, P = 0.008) had a higher risk of progression. Sixteen patients received subsequent lorlatinib, with an ORR of 28% and mPFS of 3.7 months. G2032R and L2026M resistance mutations were identified in four lorlatinib non‐responders, and in vitro studies confirmed resistance to lorlatinib. Fusion partners did not affect crizotinib outcomes. Lorlatinib was ineffective against on‐target resistance. Real‐world data showed lower TKI efficacy than clinical trials, highlighting the role of clinical and molecular factors in treatment response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, University of Groningen, University Medical Center Groningen, The Netherlands.
- Institute For Life Science and Technology, Hanze University of Applied Sciences, Groningen, The Netherlands.
- Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, The Netherlands.
ORCID-Profile: Fenneke Zwierenga
Zitieren
APA
Zwierenga, F., Dijkhuizen, C., Korthuis, P., Timens, W., Groen, H., Hiltermann, J., van den Berg, A., Drayer, L., & van der Wekken, A. (2025). The influence of ROS1 fusion partners and resistance mechanisms in ROS1 ‐ TKI ‐treated non‐small cell lung cancer patients. Molecular Oncology. https://doi.org/10.1002/1878-0261.70109
Vancouver
Zwierenga F, Dijkhuizen C, Korthuis P, Timens W, Groen H, Hiltermann J, et al. The influence of ROS1 fusion partners and resistance mechanisms in ROS1 ‐ TKI ‐treated non‐small cell lung cancer patients. Molecular Oncology. 2025. doi:10.1002/1878-0261.70109
BibTeX
@article{Zwierenga2025,
author = {Zwierenga, Fenneke and Dijkhuizen, Christa and Korthuis, Patrick and Timens, Wim and Groen, Harry and Hiltermann, Jeroen and van den Berg, Anke and Drayer, Lyndsay and van der Wekken, Anthonie},
title = {The influence of ROS1 fusion partners and resistance mechanisms in ROS1 ‐ TKI ‐treated non‐small cell lung cancer patients},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.70109}
}
EUVIMED